Erasca (ERAS) Projected to Post Earnings on Monday

Key Points

• Erasca is set to release its Q2 2025 earnings results on August 11th, with analysts predicting earnings of ($0.12) per share for the quarter.
• Shares of Erasca (ERAS) recently traded at $1.38, reflecting a 1.1% decline, with a market capitalization of approximately $389.52 million.
• Seven analysts currently have a consensus "Buy" rating for Erasca, with a price target averaging $4.57.

Erasca (NASDAQ:ERAS - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Erasca to post earnings of ($0.12) per share for the quarter.

Erasca (NASDAQ:ERAS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01. On average, analysts expect Erasca to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Erasca Price Performance

ERAS traded down $0.06 during midday trading on Friday, hitting $1.40. 490,943 shares of the company's stock traded hands, compared to its average volume of 800,601. The company has a market cap of $396.61 million, a PE ratio of -2.26 and a beta of 1.07. The stock's fifty day simple moving average is $1.47 and its 200-day simple moving average is $1.44. Erasca has a one year low of $1.01 and a one year high of $3.31.

Hedge Funds Weigh In On Erasca

A number of institutional investors have recently modified their holdings of ERAS. Creative Planning raised its position in shares of Erasca by 423.3% in the second quarter. Creative Planning now owns 244,332 shares of the company's stock valued at $310,000 after purchasing an additional 197,637 shares during the period. AQR Capital Management LLC raised its position in shares of Erasca by 594.8% in the first quarter. AQR Capital Management LLC now owns 396,202 shares of the company's stock valued at $543,000 after purchasing an additional 339,177 shares during the period. Finally, Geode Capital Management LLC raised its position in shares of Erasca by 1.6% in the second quarter. Geode Capital Management LLC now owns 4,835,642 shares of the company's stock valued at $6,143,000 after purchasing an additional 77,790 shares during the period. Institutional investors own 67.78% of the company's stock.

Analyst Upgrades and Downgrades

ERAS has been the topic of several recent research reports. HC Wainwright reaffirmed a "buy" rating and set a $6.00 price objective on shares of Erasca in a research report on Wednesday, April 30th. Guggenheim set a $3.00 price objective on shares of Erasca and gave the company a "buy" rating in a research report on Wednesday, May 14th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of "Buy" and an average price target of $4.57.

Erasca Company Profile

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.